Marilyn White


Tumor Burden Limits Liver Transplant Feasibility for HCC

November 17th 2016

Researchers have uncovered an upper limit in tumor burden after which there is a lower probability of successfully downstaging patients with hepatocellular carcinoma for liver transplantation.

Multidisciplinary Care Associated With Improved OS for HCC Patients

November 15th 2016

Multidisciplinary tumor boards led to higher utilization of guideline-recommended curative therapies, which was associated with improved overall survival for patients with early-stage hepatocellular carcinoma.

DAAs Not Associated With Increased HCC Risk in HCV Patients

November 15th 2016

Treatment with direct-acting antiviral therapy did not increase the risk of developing hepatocellular carcinoma in patients with hepatitis C virus (HCV) infection.

Researchers Validate Novel Prediction Index for HCC After Liver Transplant

November 15th 2016

A new system for gauging the probability for hepatocellular carcinoma recurrence following liver transplant surgery has proved successful.

Preclinical Studies Help to Illuminate Immunotherapy's Role in HCC

November 14th 2016

Following on their impressive success in the treatment of several other tumor types, immune-based therapies are being studied in clinical trials for hepatocellular carcinoma and are showing promising signals of efficacy.

Percutaneous and Laparoscopic RFA Outcomes Similar for HCC

November 14th 2016

Similar recurrence-free survival was demonstrated with radiofrequency ablation using percutaneous and laparoscopic methods for patients with hepatocellular carcinoma who were eligible for ablation.

Biomarkers Define Future Age of Immunotherapy in Cancer

November 13th 2016

The use of immunotherapy as a treatment for cancer is progressively increasing with a flood of recent approvals for immune checkpoint inhibitors directed against CTLA-4 and PD-1.

ERK Inhibition May Explain Regorafenib Success in Sorafenib-Resistant HCC

November 13th 2016

Efforts are under way to further evaluate the effects of regorafenib on sorafenib-resistant HCC cells, including the role of suppressing the ERK signaling pathway.